胰高血糖素和 GLP-1 受体双重激动剂生存多肽对减肥的影响:随机对照试验的荟萃分析。

IF 3.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Haijun Wan, Nuo Xu, Lijuan Wang, Yaping Liu, Somaye Fatahi, Mohammad Hassan Sohouli, Nathalia Sernizon Guimarães
{"title":"胰高血糖素和 GLP-1 受体双重激动剂生存多肽对减肥的影响:随机对照试验的荟萃分析。","authors":"Haijun Wan, Nuo Xu, Lijuan Wang, Yaping Liu, Somaye Fatahi, Mohammad Hassan Sohouli, Nathalia Sernizon Guimarães","doi":"10.1186/s13098-024-01501-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Considering the increasing prevalence of obesity/overweight, its treatment or prevention with new interventions can greatly help health and reduce its adverse effects in people. One of these new interventions is investigating the effect of Survodutide as a dual agonist of glucagon and GLP-1 receptors, which seems to be able to influence weight loss processes in different ways. In this study, we investigated the effect of injectable Survodutide on weight loss.</p><p><strong>Methods: </strong>In order to identify all randomized controlled trials that investigated the effects of Survodutide on factores related to obesity, a systematic search was conducted in the original databases using predefined keywords until August 2024. The pooled weighted mean difference and 95% confidence intervals were computed using the random-effects model.</p><p><strong>Results: </strong>The Findings from 18 treatment arms with 1029 participants indicated significant reductions in weight (WMD: -8.33 kg; 95% CI: -10.80, -5.86; I<sup>2</sup> = 99.6%), body mass index (BMI) (WMD:-4.03 kg/m<sup>2</sup>; 95% CI: -4.86, -3.20; I2 = 72.7%), and waist circumferences (WC) (WMD: -6.33 cm; 95% CI: -8.85 to -3.81; I<sup>2</sup> = 99.5%) following the Survodutide injection compared to the control group. Subgroup analysis reveals that longer interventions (more than 16 weeks) and higher doses (more than 2 mg/week) of Survodutide are associated with more significant reductions in weight and WC. These results were also observed in the meta-regression analysis.</p><p><strong>Conclusions: </strong>The results of this meta-analysis show that Survodutide is effective in reducing weight, BMI and waist circumference, especially with longer interventions and higher doses.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542446/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.\",\"authors\":\"Haijun Wan, Nuo Xu, Lijuan Wang, Yaping Liu, Somaye Fatahi, Mohammad Hassan Sohouli, Nathalia Sernizon Guimarães\",\"doi\":\"10.1186/s13098-024-01501-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Considering the increasing prevalence of obesity/overweight, its treatment or prevention with new interventions can greatly help health and reduce its adverse effects in people. One of these new interventions is investigating the effect of Survodutide as a dual agonist of glucagon and GLP-1 receptors, which seems to be able to influence weight loss processes in different ways. In this study, we investigated the effect of injectable Survodutide on weight loss.</p><p><strong>Methods: </strong>In order to identify all randomized controlled trials that investigated the effects of Survodutide on factores related to obesity, a systematic search was conducted in the original databases using predefined keywords until August 2024. The pooled weighted mean difference and 95% confidence intervals were computed using the random-effects model.</p><p><strong>Results: </strong>The Findings from 18 treatment arms with 1029 participants indicated significant reductions in weight (WMD: -8.33 kg; 95% CI: -10.80, -5.86; I<sup>2</sup> = 99.6%), body mass index (BMI) (WMD:-4.03 kg/m<sup>2</sup>; 95% CI: -4.86, -3.20; I2 = 72.7%), and waist circumferences (WC) (WMD: -6.33 cm; 95% CI: -8.85 to -3.81; I<sup>2</sup> = 99.5%) following the Survodutide injection compared to the control group. Subgroup analysis reveals that longer interventions (more than 16 weeks) and higher doses (more than 2 mg/week) of Survodutide are associated with more significant reductions in weight and WC. These results were also observed in the meta-regression analysis.</p><p><strong>Conclusions: </strong>The results of this meta-analysis show that Survodutide is effective in reducing weight, BMI and waist circumference, especially with longer interventions and higher doses.</p>\",\"PeriodicalId\":11106,\"journal\":{\"name\":\"Diabetology & Metabolic Syndrome\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542446/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetology & Metabolic Syndrome\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13098-024-01501-x\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetology & Metabolic Syndrome","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13098-024-01501-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:考虑到肥胖/超重的发病率越来越高,采用新的干预措施治疗或预防肥胖/超重会大大有助于人们的健康并减少其不良影响。作为胰高血糖素和 GLP-1 受体的双重激动剂,Survodutide 似乎能以不同的方式影响减肥过程。在这项研究中,我们调查了注射用苏伐度肽对减肥的影响:为了确定所有研究苏伐度肽对肥胖相关因素影响的随机对照试验,我们使用预先定义的关键词在原始数据库中进行了系统性搜索,搜索时间截至 2024 年 8 月。采用随机效应模型计算了汇总加权平均差和95%置信区间:来自 18 个治疗组 1029 名参与者的研究结果表明,体重(WMD:-8.33 kg;95% CI:-10.80, -5.86;I2 = 99.6%)、体重指数(BMI)(WMD:-4.与对照组相比,注射舒伐他汀后,体重指数(BMI)(WMD:-4.03 kg/m2;95% CI:-4.86,-3.20;I2 = 72.7%)和腰围(WC)(WMD:-6.33 cm;95% CI:-8.85 to -3.81;I2 = 99.5%)均有显著改善。分组分析表明,干预时间更长(超过16周)和苏伐度肽剂量更大(超过2毫克/周)与体重和腹围的显著降低有关。在荟萃回归分析中也观察到了这些结果:这项荟萃分析的结果表明,苏伐度肽能有效降低体重、体重指数(BMI)和腰围,尤其是在干预时间较长、剂量较大的情况下。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.

Background: Considering the increasing prevalence of obesity/overweight, its treatment or prevention with new interventions can greatly help health and reduce its adverse effects in people. One of these new interventions is investigating the effect of Survodutide as a dual agonist of glucagon and GLP-1 receptors, which seems to be able to influence weight loss processes in different ways. In this study, we investigated the effect of injectable Survodutide on weight loss.

Methods: In order to identify all randomized controlled trials that investigated the effects of Survodutide on factores related to obesity, a systematic search was conducted in the original databases using predefined keywords until August 2024. The pooled weighted mean difference and 95% confidence intervals were computed using the random-effects model.

Results: The Findings from 18 treatment arms with 1029 participants indicated significant reductions in weight (WMD: -8.33 kg; 95% CI: -10.80, -5.86; I2 = 99.6%), body mass index (BMI) (WMD:-4.03 kg/m2; 95% CI: -4.86, -3.20; I2 = 72.7%), and waist circumferences (WC) (WMD: -6.33 cm; 95% CI: -8.85 to -3.81; I2 = 99.5%) following the Survodutide injection compared to the control group. Subgroup analysis reveals that longer interventions (more than 16 weeks) and higher doses (more than 2 mg/week) of Survodutide are associated with more significant reductions in weight and WC. These results were also observed in the meta-regression analysis.

Conclusions: The results of this meta-analysis show that Survodutide is effective in reducing weight, BMI and waist circumference, especially with longer interventions and higher doses.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetology & Metabolic Syndrome
Diabetology & Metabolic Syndrome ENDOCRINOLOGY & METABOLISM-
CiteScore
6.20
自引率
0.00%
发文量
170
审稿时长
7.5 months
期刊介绍: Diabetology & Metabolic Syndrome publishes articles on all aspects of the pathophysiology of diabetes and metabolic syndrome. By publishing original material exploring any area of laboratory, animal or clinical research into diabetes and metabolic syndrome, the journal offers a high-visibility forum for new insights and discussions into the issues of importance to the relevant community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信